NCT04113551 - A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan | Biotech Hunter

Enrollment

17,418

Participants

Timeline

Start Date

October 1, 2019

Primary Completion Date

January 10, 2020

Study Completion Date

January 10, 2020

Conditions

Attention Deficit Disorder With Hyperactivity

Interventions

DRUG

MPH (Concerta)

MPH (Concerta) is approved for the indications of ADHD and Narcolepsy in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from Japan medical data center (JDMC) database.

DRUG

MPH (Ritalin)

MPH (Ritalin) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.

DRUG

Atomoxetine (ATO)

Atomoxetine (ATO) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.

DRUG

Guanfacine (GFC)

Guanfacine (GFC) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.

Trial Locations (1)

08560

Janssen Investigative Site, Titusville

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY